The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen, as the pharma ends work on another potential ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...

In a report released today, Peter Welford from Jefferies maintained a Sell rating on Novo Nordisk (0QIU – Research Report), with a price target ...

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion-pound ...

Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It ...

The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.

Phenotyping children with asthma based on rhinoconjunctivitis symptoms shows that rhinoconjunctivitis may not always be allergy driven.